These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2879015)

  • 1. The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
    Paxton JW
    J Pharm Pharmacol; 1986 Nov; 38(11):837-40. PubMed ID: 2879015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.
    Paxton JW; Evans PC; Singh RM
    Cancer Chemother Pharmacol; 1987; 20(1):13-5. PubMed ID: 3621447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
    Paxton JW; Jurlina JL
    Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
    Paxton JW; Evans PC; Hardy JR
    Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
    Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
    Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
    Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
    Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography.
    Jurlina JL; Paxton JW
    J Chromatogr; 1985 Aug; 342(2):431-5. PubMed ID: 3840491
    [No Abstract]   [Full Text] [Related]  

  • 8. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.
    Ganta S; Paxton JW; Baguley BC; Garg S
    J Pharm Biomed Anal; 2008 Jan; 46(2):386-90. PubMed ID: 17981420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood.
    Kestell P; Paxton JW; Robertson IG; Evans PC; Dormer RA; Baguley BC
    Drug Metabol Drug Interact; 1988; 6(3-4):327-36. PubMed ID: 3271644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a new amsacrine derivative, N-5-dimethyl-9-(2-methoxy-4-methylsulfonylamino)phenylamino-4- acridinecarboxamide, on cultured mammalian cells.
    Traganos F; Bueti C; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1987 Jan; 47(2):424-32. PubMed ID: 2431770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
    Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
    Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine.
    Robertson IG; Kestell P; Dormer RA; Paxton JW
    Drug Metabol Drug Interact; 1988; 6(3-4):371-81. PubMed ID: 3271646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
    Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC
    Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse.
    Robertson IG; Palmer BD; Paxton JW; Shaw GJ
    Xenobiotica; 1992 Jun; 22(6):657-69. PubMed ID: 1441589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleic acid binding drugs--XIV. The crystal structure of 1-methyl amsacrine hydrochloride; relationships to DNA-binding ability and anti-tumour activity.
    Neidle S; Webster GD; Baguley BC; Denny WA
    Biochem Pharmacol; 1986 Nov; 35(22):3915-21. PubMed ID: 3778515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity.
    Paxton JW; Jurlina JL
    Pharmacology; 1985; 31(1):50-6. PubMed ID: 3839584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
    Baguley BC; Finlay GJ
    J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase.
    Kettle AJ; Robertson IG; Palmer BD; Anderson RF; Patel KB; Winterbourn CC
    Biochem Pharmacol; 1992 Nov; 44(9):1731-8. PubMed ID: 1333205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence specificity of the binding of 9-aminoacridine- and amsacrine-4-carboxamides to DNA studied by DNase I footprinting.
    Bailly C; Denny WA; Mellor LE; Wakelin LP; Waring MJ
    Biochemistry; 1992 Apr; 31(13):3514-24. PubMed ID: 1554731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.